Skip to Content

Oral Decitabine–Cedazuridine Is Equivalent to Intravenous Decitabine in MDS or CMML

In this MEDtalk, Professor Michael Savona from Vanderbilt University shares results from the ASCERTAIN trial investigating the oral combination of decitabine and cedazuridine (DEC-C) for treatment of myelodysplastic syndromes or chronic myelomonocytic leukaemia vs intravenous decitabine. The trial explores the potential of this oral treatment to provide a convenient, effective alternative to traditional intravenous therapies. The results support use of oral decitabine–cedazuridine vs intravenous decitabine.

Michael Savona

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top